H2 2017 Telomerase Reverse Transcriptase Pipeline Review

"The Report Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

According to the recently published report 'Telomerase Reverse Transcriptase - Telomerase Reverse Transcriptase'; Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) pipeline Target constitutes close to 31 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes.

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Telomerase reverse transcriptase is a catalytic subunit of the enzyme telomerase. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. It modulates Wnt signaling. It plays important role in aging and anti-apoptosis.

The report 'Telomerase Reverse Transcriptase - Telomerase Reverse Transcriptase' outlays comprehensive information on the Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Get Sample Copy Of This Report @
https://www.marketresearchreports.biz/sample/sample/1343234

It also reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 8, 2, 1, 8 and 4 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Hematological Disorders, Immunology, Male Health and Metabolic Disorders which include indications Non-Small Cell Lung Cancer, Breast Cancer, Prostate Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Hepatocellular Carcinoma, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Amyotrophic Lateral Sclerosis, Aplastic Anemia, Atherosclerosis, Benign Prostatic Hyperplasia, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Cervical Cancer, Gastroesophageal (GE) Junction Carcinomas, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone-Sensitive Prostate Cancer, Leukemias, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Muscle Invasive Bladder Cancer (MIBC), Myelodysplastic Syndrome, Myelofibrosis, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Premature Ageing and Renal Cell Carcinoma.

View Report @ https://www.marketresearchreports.biz/reports/1343234/telomerase-reverse-transcriptase-hest2-or-telomerase-catalytic-subunit-or-telomerase-associated-protein-2-or-tert-or-ec-27749-pipeline-review-h2-2017-market-research-reports

Scope

- The report provides a snapshot of the global therapeutic landscape for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)
- The report reviews Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics and enlists all their major and minor projects
- The report assesses Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics

Send An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/1343234

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Overview 9
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Development 10
Products under Development by Stage of Development 10
Products under Development by Therapy Area 11
Products under Development by Indication 12
Products under Development by Companies 15
Products under Development by Universities/Institutes 20
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Assessment 22
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Companies Involved in Therapeutics Development 28
Argos Therapeutics Inc 28
Asterias Biotherapeutics Inc 28
e-Therapeutics Plc 29
F. Hoffmann-La Roche Ltd 29
Inovio Pharmaceuticals Inc 30
Invectys SA 30
Johnson & Johnson 31
Komipharm International Co Ltd 31
Mediolanum farmaceutici SpA 32
Telocyte LLC 32
TILT Biotherapeutics Ltd 33
Ultimovacs AS 33
Vaxon Biotech 33
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Drug Profiles 35
AGS-499 - Drug Profile 35
Product Description 35
Mechanism Of Action 35

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
Email: sales@marketresearchreports.biz

This release was published on openPR.